ECSP22037660A - Agonistas del receptor npy2 - Google Patents

Agonistas del receptor npy2

Info

Publication number
ECSP22037660A
ECSP22037660A ECSENADI202237660A ECDI202237660A ECSP22037660A EC SP22037660 A ECSP22037660 A EC SP22037660A EC SENADI202237660 A ECSENADI202237660 A EC SENADI202237660A EC DI202237660 A ECDI202237660 A EC DI202237660A EC SP22037660 A ECSP22037660 A EC SP22037660A
Authority
EC
Ecuador
Prior art keywords
receptor agonists
analogs
npy2 receptor
relates
npy2
Prior art date
Application number
ECSENADI202237660A
Other languages
English (en)
Inventor
Soren Pedersen
Albert Brennauer
Charlotte Madsen
Peter Haebel
Stefan Peters
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of ECSP22037660A publication Critical patent/ECSP22037660A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2271—Neuropeptide Y

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La invención se refiere a análogos de PYY que tienen alanina en la posición 4, lisina en la posición 7, QRY como el extremo del terminal C y un grupo de prolongación de semivida. Los análogos de la invención son solubles a alrededor de pH 6 y 7. La invención también se refiere a composiciones farmacéuticas que comprenden tales análogos de PYY y al uso médico de los análogos.
ECSENADI202237660A 2019-11-11 2022-05-11 Agonistas del receptor npy2 ECSP22037660A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19208394 2019-11-11
PCT/EP2020/081513 WO2021094259A1 (en) 2019-11-11 2020-11-09 Npy2 receptor agonists

Publications (1)

Publication Number Publication Date
ECSP22037660A true ECSP22037660A (es) 2022-06-30

Family

ID=68531488

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202237660A ECSP22037660A (es) 2019-11-11 2022-05-11 Agonistas del receptor npy2

Country Status (18)

Country Link
US (2) US20210139548A1 (es)
EP (1) EP4058047A1 (es)
JP (1) JP2023500895A (es)
KR (1) KR20220100925A (es)
CN (1) CN114641303A (es)
AR (1) AR120440A1 (es)
AU (1) AU2020384729A1 (es)
CA (1) CA3156452A1 (es)
CL (1) CL2022001227A1 (es)
CO (1) CO2022006046A2 (es)
CR (1) CR20220206A (es)
EC (1) ECSP22037660A (es)
IL (1) IL292601A (es)
JO (1) JOP20220110A1 (es)
MX (1) MX2022005661A (es)
PE (1) PE20221168A1 (es)
TW (1) TW202134263A (es)
WO (1) WO2021094259A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020384729A1 (en) 2019-11-11 2022-04-14 Boehringer Ingelheim International Gmbh NPY2 receptor agonists
MX2023001532A (es) * 2020-08-07 2023-03-08 Boehringer Ingelheim Int Agonistas del receptor npy2 solubles.
WO2024038067A1 (en) 2022-08-18 2024-02-22 Boehringer Ingelheim International Gmbh Combination therapy comprising long acting glp-1/glucagon and npy2 receptor agonists
WO2024133382A1 (en) * 2022-12-21 2024-06-27 Boehringer Ingelheim International Gmbh Glp1/gip/npy2 receptor triple agonists

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2417980A1 (en) 2004-02-11 2012-02-15 Amylin Pharmaceuticals Inc. Hybrid polypeptides with selectable properties
MXPA06010347A (es) 2004-03-17 2007-06-19 7Tm Pharma As Agonistas de receptor selectivo de y2 para intervenciones terapeuticas.
KR101272402B1 (ko) 2004-12-13 2013-06-10 아스트라제네카 파마수티컬스 엘피 췌장 폴리펩티드 족 모티프, 폴리펩티드 및 이를 포함하는방법
WO2007065808A2 (en) 2005-12-07 2007-06-14 F. Hoffmann-La Roche Ag Neuropeptide-2 receptor-agonists
WO2008101017A2 (en) 2007-02-15 2008-08-21 Indiana Unversity Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
WO2008152403A1 (en) 2007-06-15 2008-12-18 Zealand Pharma A/S Glucagon analogues
KR20100098628A (ko) 2007-11-14 2010-09-08 아밀린 파마슈티칼스, 인크. 비만 및 비만 관련 질환 및 장애의 치료 방법
FR2934058B1 (fr) 2008-07-15 2010-09-24 Centre Nat Rech Scient Dispositif de projection interferometrique a trois ouvertures pour produire une tache constituee de structures fines
JP5635531B2 (ja) 2008-12-15 2014-12-03 ジーランド ファーマ アクティーゼルスカブ グルカゴン類似体
UA104605C2 (uk) 2008-12-15 2014-02-25 Зіленд Фарма А/С Аналоги глюкагону
WO2010070252A1 (en) 2008-12-15 2010-06-24 Zealand Pharma A/S Glucagon analogues
ES2502218T3 (es) 2008-12-15 2014-10-03 Zealand Pharma A/S Análogos de glucagón
CA2767792A1 (en) 2009-07-13 2011-01-20 Zealand Pharma A/S Acylated glucagon analogues
US20130040877A1 (en) 2009-09-18 2013-02-14 Novo Nordisk A/S Long-acting y2 receptor agonists
WO2011058165A1 (en) 2009-11-13 2011-05-19 Novo Nordisk A/S Long-acting y2 receptor agonists
AR081975A1 (es) 2010-06-23 2012-10-31 Zealand Pharma As Analogos de glucagon
US9169310B2 (en) 2010-06-24 2015-10-27 Zealand Pharma A/S Glucagon analogues
PL2718316T3 (pl) 2011-06-10 2020-06-29 Novo Nordisk A/S Polipeptydy
JP2015502380A (ja) 2011-12-23 2015-01-22 ジーランド ファーマ アクティーゼルスカブ グルカゴン類似体
TR201815338T4 (tr) 2012-05-03 2018-11-21 Zealand Pharma As Gıp-glp-1 dual agonist bileşikleri ve yöntemler.
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
EA201591839A1 (ru) 2013-05-02 2016-05-31 Глаксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Терапевтические пептиды
AR097701A1 (es) 2013-09-19 2016-04-13 Zealand Pharma As Análogos de amilina
DK3057984T3 (en) 2013-10-17 2018-10-08 Zealand Pharma As ACYLED GLUCAGON ANALOGS
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
CN105829339B (zh) 2013-11-06 2021-03-12 西兰制药公司 胰高血糖素-glp-1-gip三重激动剂化合物
EP3470422A1 (en) 2013-11-14 2019-04-17 KeyBioscience AG Calcitonin mimetics for treating diseases and disorders
RS59026B1 (sr) * 2013-11-15 2019-08-30 Novo Nordisk As Selektivna pyy jedinjenja i njihova upotreba
WO2016146739A1 (en) 2015-03-18 2016-09-22 Zealand Pharma A/S Amylin analogues
CA2980978A1 (en) 2015-04-16 2016-10-20 Zealand Pharma A/S Acylated glucagon analogue
AU2016275735B2 (en) 2015-06-12 2020-02-06 Novo Nordisk A/S Selective PYY compounds and uses thereof
WO2016198624A1 (en) 2015-06-12 2016-12-15 Sanofi Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
CA3010265A1 (en) 2015-12-31 2017-07-06 Hanmi Pharm. Co., Ltd. Long-acting conjugate of triple glucagon/glp-1/gip receptor agonist
US10975152B2 (en) 2016-05-03 2021-04-13 The Scripps Research Institute TrkB agonist antibodies and methods for treating an ocular degenerative disorder characterized by degeneration of retinal ganglion cells (RGCs)
AR109514A1 (es) 2016-09-09 2018-12-19 Zealand Pharma As Análogos de amilina
JOP20190097A1 (ar) 2016-10-27 2019-04-28 Janssen Pharmaceutica Nv الجلوبولينات المناعية واستخداماتها
TW201833132A (zh) 2016-12-02 2018-09-16 法商賽諾菲公司 作為肽類ｇｌｐ１／升糖素／ｇｉｐ三重受體激動劑之新穎化合物
TW201833131A (zh) 2016-12-02 2018-09-16 法商賽諾菲公司 作為胜肽類ｇｌｐ１／升糖素／ｇｉｐ受體促效劑之新化合物
CN108289005B (zh) 2017-01-09 2021-06-29 中兴通讯股份有限公司 信令发送、接收方法及装置
GB201704429D0 (en) 2017-03-21 2017-05-03 Keybioscience Ag Calcitonin mimetics for treating diseases and disorders
US10793634B2 (en) 2017-06-09 2020-10-06 Boehringer Ingelheim International Gmbh Anti-TrkB antibodies
GB201720188D0 (en) 2017-12-04 2018-01-17 Imperial Innovations Ltd Analogues of PYY
TWI749381B (zh) * 2018-11-01 2021-12-11 美商美國禮來大藥廠 蛋白質酪胺酸-酪胺酸類似物及其使用方法
AU2020384729A1 (en) 2019-11-11 2022-04-14 Boehringer Ingelheim International Gmbh NPY2 receptor agonists

Also Published As

Publication number Publication date
JOP20220110A1 (ar) 2023-01-30
CL2022001227A1 (es) 2023-02-03
TW202134263A (zh) 2021-09-16
WO2021094259A1 (en) 2021-05-20
US20210139548A1 (en) 2021-05-13
US20230340039A1 (en) 2023-10-26
AU2020384729A1 (en) 2022-04-14
AR120440A1 (es) 2022-02-16
EP4058047A1 (en) 2022-09-21
JP2023500895A (ja) 2023-01-11
CO2022006046A2 (es) 2022-05-20
PE20221168A1 (es) 2022-07-25
US12054525B2 (en) 2024-08-06
MX2022005661A (es) 2022-09-07
KR20220100925A (ko) 2022-07-18
CA3156452A1 (en) 2021-05-20
CR20220206A (es) 2022-06-16
CN114641303A (zh) 2022-06-17
IL292601A (en) 2022-07-01

Similar Documents

Publication Publication Date Title
ECSP22037660A (es) Agonistas del receptor npy2
CL2023000357A1 (es) Agonistas del receptor npy2 solubles
CL2018003319A1 (es) Compuestos de mic-1 y usos de estos.
MY187047A (en) Selective pyy compounds and uses thereof
CL2019003441A1 (es) Puestos de mic-1 y usos de estos.
NZ743488A (en) Controlled-release cnp agonists with low initial npr-b activity
SA521421715B1 (ar) تركيبات سيماجلوتيد ثابتة واستخداماتها
NZ743489A (en) Controlled-release cnp agonists with low npr-c binding
CL2021003272A1 (es) Composición farmacéutica parenteral del agonista dual glp1/2
PH12020551018A1 (en) Oral delivery of glp-1 peptide analogs
BR112022002720A2 (pt) Formulações de conjugados de benzazepinas e usos das mesmas
BR112022006297A2 (pt) Agonistas de receptor de npy2
EA202192475A1 (ru) Способ получения стабильных пептидных составов
MX2016004660A (es) Composiciones de peptido novedosas.
EA202290107A1 (ru) Фармацевтические композиции на основе пептидов, являющихся коагонистами глюкагона и glp-1
EA202191511A1 (ru) Составы на основе аналога пептида оксинтомодулина
EA202091375A1 (ru) БИЦИКЛИЧЕСКИЕ ПЕПТИДНЫЕ ЛИГАНДЫ, ОБЛАДАЮЩИЕ СПЕЦИФИЧНОСТЬЮ К EphA2